iX Biopharma Ltd. (SGX:42C)

Market Cap	218.03M +973.2%
Revenue (ttm)	7.23M +3.3%
Net Income	-5.95M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,386,200
Average Volume	10,991,380
Open	0.2100
Previous Close	0.2050
Day's Range	0.2000 - 0.2100
52-Week Range	0.0150 - 0.2500
Beta	n/a
RSI	56.96
Earnings Date	May 10, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 35
• Stock Exchange: Singapore Exchange
• Ticker Symbol: 42C

Financial Performance

In fiscal year 2025, iX Biopharma's revenue was 7.77 million, an increase of 30.34% compared to the previous year's 5.96 million. Losses were -10.14 million, -6.05% less than in 2024.